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Background: Hepatocellular carcinoma (HCC) is the most prevalent hepatic cancer worldwide. Currently, a targeted
therapy via monoclonal antibodies (mAbs) specific to tumor-associated antigen is undergoing continual development
in HCC treatment.
Methods: In this regard, after establishing and consequently exploring Hep88 mAb’s tumoricidal effect on
hepatocellular carcinoma cell line (HepG2 cell line), the Hep88 mAb’s specific antigens from both membrane
and cytoplasmic fractions of HepG2 cell line were identified by 2-D gel electrophoresis and western blot
analysis. After in-gel digestion and subsequent analysis by liquid chromatography-mass spectrometry (LC-MS),
mortalin (HSPA9) and alpha-enolase were identified. The recombinant proteins specific to Hep88 mAb were
cloned and expressed in E. coli BL21(DE3). Moreover, alteration of HepG2 and Chang liver cell line after being
induced by Hep88 mAb for 1–3 days was investigated using a transmission electron microscope.
Results: The result demonstrated that Hep88 mAb can bind to the recombinant mortalin (HSPA9) and alpha-enolase.
In addition, the gradual appearing of mitochondria vacuolization and endoplasmic reticulum dilatation were observed.
Those characteristics might be explained by the paraptosis-like program cell death (PCD), which is induced by the
binding of Hep88 mAb to mortalin (HSPA9). Mortalin depletion resulting from the formation of Hep88 mAb-mortalin
(HSPA9) complex might initiate transcription-independence of p53-mediated apoptosis. Additionally, Hep88mAb-
alpha-enolase complex might initiate HepG2 cells energy exhaustion by glycolysis pathway obstruction.
Conclusion: These fascinating results imply that Hep88 mAb might be a promising tool for the development of an
effective treatment of HCC in the next decade.
Keywords: Alpha-enolase, Hepatocellular carcinoma, Monoclonal antibody, Mortalin (HSPA9), Paraptosis-like program
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Hepatocellular carcinoma (HCC) is the second-most lead-
ing cause of cancer-related mortality in the world, ac-
counting for up to approximately 698,000 deaths in
2008 globally [1]. Its prevalence and mortality rate varies
from region to region, and is noticeably lower in most
developed areas (5–10 per 100,000), but is detected to* Correspondence: panadda_rojpibulstit@hotmail.com
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article, unless otherwise stated.be gradually higher in developing countries (>20 per
100,000), including the South-East Asian countries [2]. In
Thailand, the third leading new cancer cases in males and
the fifth in females [3-5] are attributed to HCC, whereas
the mortality rates rank it as the top leading cancer
[6,7]. The main etiology for HCC in Thailand is hepatitis
B virus (HBV) infection [8,9], while, globally principle eti-
ologies for HCC consist of the chronic infection of hepa-
titis B virus (HBV), hepatitis C virus (HCV), alcohol and
aflatoxin ingestion [10,11].
Currently, technologies in treatment of the HCC are be-
ing continuously developed and include hepatic resectiontral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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ethanol injection: PEI [12], transcatheter oily chemoem-
bolization: TOCE [13], radiofrequency ablation (RFA)
[14]. However, the mortality rates of the HCC patients
are still increasing annually. The survival rates depend on
many factors, but especially on tumor size and staging
[15-17]. This trend is being caused by a lack of sensitive
and specific early detection, and effective treatment for
the cure of any remaining cancer cells. Alternatively, a tar-
geted therapy such as the immunotherapy via monoclonal
antibodies (mAbs) specific to tumor-associated antigen
has become a fascinating tool for the targeting of specific
HCC cells that are critical to tumor progression while
reducing toxicity to normal cells [18-20]. The possible
mechanisms of anti-tumor effect of mAbs might be in-
volved in blocking the growth-factors receptor, inducing
apoptosis or activating complement cascade resulting in
tumor cell lysis and phagocytosis by macrophage [21-23].
With the advantages of the mAb therapy, we previ-
ously established and characterized the cytotoxic ac-
tivity of Hep88 mAb, a novel monoclonal antibody that
fights against HCC [24-26]. Our prior studies showed that
Hep88 mAb has tumoricidal activity against HCC (HepG2
cell line), while harmless to the normal liver cell line
(Chang liver) [25,26]. Additionally, recognizing proteins
against Hep88 mAb have been found not only on cell
membranes, but also on the cytoplasmic compartment.
In addition, from our previous study, intracellular vacuoli-
zation, as well as endoplasmic reticulum and mitochondria
dilatation, have been noticed after a 3-day incubated HepG2
with Hep88 mAb [26]. These ultra-structural changes in-
duced HCC death via paraptosis-like program cell death
(PCD) [27,28]. So, we then hypothesized that the killing
effect of Hep88 mAb through a paraptosis-like PCD path-
way is triggered by binding with its-specific proteins.
Therefore, in this study, Hep88 mAb’s specific antigens
were analyzed by 2D-gel electrophoresis and western blot
followed by LC-MS. Two specific proteins including mor-
talin (HSPA9) and alpha-enolase were identified. The
cDNA encoding these 2 proteins isolated from HepG2
cells were cloned into the expression plasmid pET17b and
expressed in E. coli BL21(DE3). Their specific recognitions
as Hep88 mAb are rechecked by the western blotting tech-
nique. Moreover, the tumoricidal effect of Hep88 mAb
against the HepG2 and Chang liver cell line during a 1-3-
day period was also monitored using a transmission elec-
tron microscope. All of these promising results might lead
us to the identification of pharmacological interventions of
Hep88 mAb against HCC in the near future.
Methods
Cell lines and mAb
Human HCC cell lines, HepG2 cells (American Type
Culture Collection [ATCC] HB8065), and normal livercell line, Chang liver (American Type Culture Collection
[ATCC] CCL-13) were cultured in RPMI 1640, supple-
mented with 10% fetal bovine serum (Biochrom AG,
Germany). Both cell lines were maintained at 37°C in a
CO2 incubator and subcultured every 3–4 days. Hep88
mAb, the anti-HCC mouse mAb, was produced as previ-
ously described [24].
2D-Gel electrophoresis
Total proteins from cytoplasmic and membranous parts
of 4.5 × 108 cells of HepG2 cell lines were extracted,
cleaned up and separated by two-dimensional gel electro-
phoresis as previously described by using immobilized pH
gradient (IPG) strips with pI 3–10 and broadening IPG
strip with pI 4–7, followed by 12.5% SDS-PAGE [29].
Western blotting analysis
The gels were subsequently transferred to nitrocellulose
membrane (Amersham Pharmacia Biotech Co.) using a
semi-dry transblot technique at 6 V, 70 minutes as de-
scribed by Towbin [30] and Burnette [31]. After blocking
the transferred membrane in TBST blocking solution
(containing 20 mM TBS pH 7.5, 5% skim milk and 0.1%
Tween-20), the membrane was then incubated for 2 hours
with Hep88 mAb (dilution 1:2,000) as the primary anti-
body at room temperature. Thereafter, the membrane was
3× washed in TBST and 1-hour incubated with 1:3,000 al-
kaline phosphatase-Rabbit Anti-Mouse IgG (H + L) Con-
jugate (ZyMax™ Grade, Invitrogen) at room temperature.
The bounded proteins were color-visualized with BCIP/
NBT substrate solution (Invitrogen) according to the man-
ufacturer’s instruction.
Protein identification
The interested protein spots were consequently in-gel
trypsin digested and further analyzed by LC-MS. All ob-
tained MS/MS raw data were submitted to online data-
base search using the MASCOT (Matrix Science, U.K.)
against NCBI’s database. Search parameters were set
as follows: peptide tolerance (0.2 Da), NCBInr database,
Homo sapiens (taxonomy), carbamidomethylation of cyst-
eine (fixed modification), and methionine oxidation (vari-
able modification).
Plasmids construction of mortalin (HSPA9) and alpha-
enolase
Total RNA was extracted from HepG2 cell line by TRIzol
reagent (Invitrogen) according to the manufacturer’s in-
struction. Ten micrograms of total RNA were then used
to synthesize cDNA with random hexamers (Invitrogen)
and oligo (dT) primers (Invitrogen) by using Superscript
reverse transcriptase (Invitrogen). Human mortalin (NCBI
Reference Sequence: NP_004125.3) and alpha enolase
isoform [Homo sapiens] (NCBI Reference Sequence:
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reaction (PCR). The PCR product of these two pro-
teins were performed with BamHI-NdeI fragment re-
striction site and cloned in pBluescript (Stratagene). The
forward primer sequence for mortalin (HSPA9) was 5′-
AAGCTTCATATGATAAGTGCCAGCCGAGCTGCA-3’
and the reverse primer was 5′-GGATCCTTACTGTT
TTTCCTCCTTTTGATCTTCCTT-3’, while the sequence
for α-enolase was 5′-AAGCTTCATATGTCTATTCTCA
AGATGCATGCCAG-3’ with 5′-GGATCCTTACTTGGC
CAAGGGGTTTCTGAAGTTC-3’ as the reverse primer.
The italic DNA sequence represented an NdeI site on for-
ward primer and a BamHI site on reverse primer, while
the bold alphabet ATG on forward primer and the bold
TTA on reverse primer referred to start and stop codon,
respectively. PCR products were subsequently subject to
preliminary analysis on submarine agarose gel electro-
phoresis and the DNA fragment was purified by using the
Nucleospin extraction kit (Nucleospin). After resolving
the purified DNA fragment in double-distilled water, the
purified DNA fragment was cloned into pGEM-T Easy
plasmid and transformed into E. coli DH5 alpha. The re-
combinant plasmid harboring HSPA9 and α-enolase were
selected for colonies PCR screening after 37°C overnight
incubation on LB/ampicillin plates. The recombinant plas-
mids were extracted and double-digested with BamHI-
NdeI. The nucleotide sequences of the recombinant
plasmid containing HSPA9 or α-enolase DNA fragment
flanked with BamHI-NdeI restriction sites were determined
(Macrogen DNA sequencing Service, Korea).
Proteins expression
The plasmid containing a corrected sequence of HSPA9 or
α-enolase were ligated to an expression vector, pET17b
(Novagen) at BamHI-NdeI cloning sites. The recombinant
plasmid in pET17b was then transformed into E. coli BL21
(DE3) and incubated at 37°C overnight on LB/ampicillin
plates. To express these 2 proteins, the E. coli carrying
HSPA9 or α-enolase genes were cultivated at 37°C over-
night in LB/ampicillin broth. The overnight culture was di-
luted 10-fold into fresh LB/ampicillin medium and grown
at 37°C until reaching a lag phase (at 0.6-0.7 OD600).
Isopropyl-β-D-thiogalactopyranoside (IPTG) at a final con-
centration of 1 mM was then used to induce protein ex-
pression. Cells were harvested after induction for 6 hours
at 30°C. Total protein extracted from induced recombinant
cells were extracted and analyzed by 10% SDS-PAGE. After
running at 100 volts for 2 hours, the gel was visualized by
staining with 0.3% Coomassie blue R250.
Sequential ultrastructure examination by a transmission
electron microscope
HepG2 and Chang liver cell lines (1 × 106 cells) were
cultured in a completed medium with or without Hep88mAb at IC50 concentration (12.5 μg/mL) for 0, 1, 2 and
3 days. The preparation procedures for the transmission
electron microscope examination, including cell harvest-
ing, glutaraldehyde/paraformaldehyde fixation, osmium
post fixation, graded step alcohol dehydration and resin
polymerization, were done as previously described [26].
Subsequently, 60–90 nm ultrathin sections were performed
by a Porter-Blum MT-2 ultramicrotome and investigated
under a Philips CM 100 TEM at 80 kV.
Results
Hep88 mAb’s membrane specific antigens detected by
2D-PAGE and western blotting analysis
Proteomic study by two-dimensional gel electrophoresis
(IEF of pI 3–10 and pI 4–7 followed by 12.5% SDS-PAGE)
of membranous and cytoplasmic parts of HepG2 are illus-
trated in Figure 1A-B and 1C-D, respectively. Protein spots
of interest, indicated by the arrows, were visualized after
subsequent immunoblotting of membranous and cyto-
plasmic proteins on 2-D gel with Hep88 mAb, as shown
in Figure 1E-F and 1G-H, respectively. LC-MS analysis
and peptide sequence comparison with online data base of
those protein spots revealed the matched proteins as
shown in Figure 2. The summary of matched proteins
from both membrane and cytoplasmic fraction in each pI
are shown in Figure 3.
Cloning and expression of recombinant proteins
After effectively cloning into pET-17b, and transforming
into E. coli BL21 (DE3), the apparent molecular weights of
74 kDa and 48.1 kDa proteins were detected in pET17b-
HSPA9 and pET17b-α-enolaseclones, respectively (Figure 4
left). The specificity of those recombinant proteins to
Hep88 mAb was then visualized by western blotting tech-
nique as shown in Figure 4 right.
Sequential ultrastructure examination by a transmission
electron microscope
After incubation the ultrathin section of Chang and
HepG2 cell line with the Hep88 mAb and visualization
under transmission electron microscope, mitochondria
vacuolization and endoplasmic reticulum dilatation were
gradually observed on days 0, 1, 2 and 3 only in HepG2
treated with Hep88 mAb as shown in Figure 5.
Discussion
HCC therapeutic via monoclonal antibody treatments are
now being investigated worldwide with the advantages of
non-hazardous and non-invasiveness [18-20,32]. In this re-
gard, we previously produced and characterized the new
tumoricidal monoclonal against HCC: Hep88 mAb [24-26].
By 2D-PAGE and western blot analysis showed that Hep88
mAb recognized both membrane- and cytoplasmic pro-
teins. To confirm the specificity of Hep88 mAb against two
Figure 1 (See legend on next page.)
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Figure 1 Proteomic pattern (IEF of pI 3-10 and pI 4-7 followed by 12.5% SDS-PAGE) and immuno-blotting profiles of membranous and
cytoplasmic part of HepG2 (1stAb: Hep88 mAb, dilution 1: 100; 2ndAb: rabbit anti-mouse Ab, dilution 1: 3,000; Detection system: alkaline
phosphatase & BCIP/NBT). (A-B) Coomassie blue staining of 2-D gel of membrane proteins with IEF of pI 3-10 and pI 4-7, respectively.
(C-D) Coomassie blue staining of 2-D gel of cytoplasmic proteins with pI 3-10 and 4-7, respectively. (E-F) Immuno-staining of membrane
proteins with Hep88 mAbwith pI 3-10 and 4-7, respectively. (G-H) Immuno-staining of cytoplasmic proteins with Hep88 mAb with pI 3-10
and 4-7, respectively. Protein spots which were further analyzed by LC-MS were indicatedby red arrows.
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Figure 2 Identified proteins from membrane and Cytoplasmic fractions of HepG2 cells by LC/MS/MS according to the spot number,
Swiss-protein accession number, theoretical pI and its molecular weight.
























Membrane Alpha -Enolase 40-
50
6-7
HMW heat shock protein 60-
70
5-6
Glutamate Dehydrogenase 55 7.3
Aldehyde Dehydrogenase 61 8
PEPCK 70 7.4
tubulin 50 4.7
nucleobindin 2 [Homo 
sapiens]
50 5
ATP synthase 56 5.26
Figure 3 Grouping of the possible proteins from each sub-cellular fraction and each pI in relation with theoretical pI and its
molecular weight.
Figure 4 Expression of HSPA9 and α-enolase (Left) Coomassie blue staining (Right) Immuno-blotting staining with Hep88 mAb (1stAb:
Hep88 mAb, dilution 1: 2,000; 2ndAb: rabbit anti-mouse Ab, dilution 1: 3,000; Detection system: alkaline phosphatase & BCIP/NBT).
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HepG 2 cell line
Figure 5 TEM micrograph of subcellular alterations of the Chang (left) and HepG2 cell line (right) after incubation with Hep88 mAb:
day 0 (A, E), day 1 (B, F), day 2 (C, G), day 3 (D, H). Gradual intracellular vacuolization within mitochondria and ER dilation were observed only
in HepG2 treated cell (right).
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α-enolase proteins were expressed in E. coli and analyzed
by western blot. The ability of Hep88 mAb to trigger the
HCC cell death was monitored by a transmission electron
microscope. Gradual sub-cellular changes during treatment
with Hep88 mAb over a period of 3 days were found.
HSPA9 is a 74 kDa protein, composed of 679 amino acids.
It was found both in mitochondria and extra-mitochondrial
areas, including cytoplasm and plasma membrane [33,34].
Because of its multifunction, it was also known as
mortalin (an in-cell mortality in mice), mthsp70 (a mito-
chondrial transport protein in humans) and GRP75 (the
glucose response protein in rats) [35]. For cancer modal-
ity, it has been proved to be an anti-apoptotic element
by its interaction with p53, the tumor-suppressor protein
which then inactivates either its transcriptional-dependent
or –independent properties and finally diminishes its
apoptotic functions. Up to the present moment, the
association of over-expressed HSPA9 and HCC has been
widely reported [36-39]. It is presently said to be a new
potential targeted cancer therapy, either by its capacity
to disrupt the interaction between GRP75 and p53 or
to inhibit its expression [40-43].
For the other protein: α-enolase (ENOA), it is a 48 kDa
protein, composed of 434 amino acids. It acts as an enzyme
catalyzes the reversible reaction of 2-phosphoglycerate
(2-PG) to phosphoenolpyruvate (PEP) in a phase II gly-
colysis pathway. ENOA is the predominant isoform that
expressed in almost all adult human tissues. It is also
expressed on the cancer cell surface, acting as a plasmino-
gen activator that leads to activate plasminogen into plas-
min [44,45]. This event was further mediated through
fibrinolytic consequences resulting in the metastasis of
many cancers [46]. For HCC, it has been reported that
ENOA over-expression is involved in tumor progression
and venous invasion [47,48]. At this moment, ENOA is a
remarkable protein relevant to cancer therapeutic care in
a new era [49].
After an expression of recombinant human HSPA9
(mortalin) and α-enolase and subsequently immunoblot-
ting against Hep88 mAb, it was found that both proteins
are definitely Hep88 mAb’s specific antigens. From previous
reports, up-regulation of HSPA9 (mortalin) was associated
with HCC metastasis and recurrence [35,50]. As is now
known, HSPA9 is one of the chaperone proteins whose
main functions consist in aiding the folding/unfolding
or assembly/disassembly of other multi-proteins that
are to be recovered to normal function after stress situ-
ation [51]. HSPA9 was found to localize either on plasma
membranes, cytoplasmic areas or in mitochondrial parts.
Consequently, in cooperation with other proteins, it also
functions in concert toward cell proliferation, senescence
and tumorigenesis [34,52]. Wadhwa et al. demonstrated
that HSPA9 (mortalin) acted as anti-apoptotic factor bypreventing p53 activation in cytoplasm [53]. From this
view, the ongoing-research is now being pointing out
as a striking target for cancer therapy by regaining p53
activity through interfering in the interaction of p53-
mortalin complex, as, for example: by its antisense RNA,
ribozymes, siRNA or a chemical targeting mortalin-p53
interaction such as MKT-077 (a cationic rhodacyanine
dye) [41,42,54]. From this point, it has been clearly shown
in this present study that Hep88 mAb can react directly
with the recombinant human mortalin. In addition, grad-
ual intracellular vacuolization within mitochondria and
ER dilation were observed under TEM only in HepG2
after incubation with Hep88 mAb. These subcellular
alterations are compatible with those findings in paraptosis-
like programmed cell death (PCD) as described by Sperandio
et al. [27] and Wyllie and Golstein, 2001 [28]. These find-
ings, however, did not match with those as seen in the
senescent-arrested cells, i.e. having a large number of
electron-dense structures, more lysosomes with a multi-
layered appearance, as well as an increase in branched or
fused mitochondria as reviewed by Terman A et al. [55].
Additionally, these alterations also differed from end re-
sults found in apoptotic cell death which included
DNA fragmentation, membrane blebbing or cytoplas-
mic shrinkage as summarized by Motyl et al. [56]. How-
ever, the paraptosis-like PCD which followed the formation
of Hep88 mAb-mortalin complex in the cytoplasm
might be explained by the releasing of p53 out from
p53-mortalin complex, so that the p53 then acted
through a transcription-independent pathway by the in-
duction of LMP (lysosomal membrane permeabilization)
as discussed by Li et al. [57]. This event resulted in the re-
leasing of various lysosomal protease - i.e., granzyme B,
cathepsins B and D etc., which finally activated the cells
into a state of paraptosis [58].
In addition, the specific recognizable characteristics be-
tween α-enolase and Hep88 mAb were also verified in this
present study. At this moment in time, α-enolase is be-
lieved to be involved in cell migration and cancer metasta-
sis by its action as a plasminogen-binding receptor [44,45].
Moreover, the correlation between tumor progression and
up-regulation of this enzyme has been reported [46]. This
finding might be explained by the increased energy de-
mand in cancer cells resulting in forcing the forward feed-
ing of the glycolysis pathway, well-known as the Warburg
effect [59]. In this sense, it might be postulated that the
effect of Hep88 mAb-α-enolase complex disturbed the
Warburg effect and consequently left the cells to die from
energy exhaustion. This synergistic effect between the ATP
depletion phenomenon along with the effect of the Hep88
mAb-mortalin complex might finally lessen the capacity of
the HCC to remain alive.
However, from this study it might be suggested that
Hep88 mAb can recognize the share of antigenic epitopes
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sibly either by their relatively identical 3-D motifs or their
similar amino acid sequences at the antigenic determin-
ant, as reported by Piotrowska et al. [60]. It is anticipated
that this effect will not limit the Hep88 mAb’s efficacy,
but, instead, will increase sensitivity of its usage both in
therapeutic and diagnosis areas.
Conclusions
On the basis of these results, Hep88 mAb may well be a
new candidate as a monoclonal antibody in the cure of
HCC in the near future. However, the existence of its
mechanism in the killing of HCC has yet to be proven
thus far. But this preliminary study forcefully prods us to
learn more about the therapeutic tool of Hep88 mAb.
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